Capmatinib and savolitinib, selective
MET inhibitors, are widely used to treat various
MET-positive cancers. In this study, we aimed to determine the effects of these inhibitors on
MET-amplified gastric cancer (GC) cells. Methods: After screening 37 GC cell lines, the following
[...] Read more.
Capmatinib and savolitinib, selective
MET inhibitors, are widely used to treat various
MET-positive cancers. In this study, we aimed to determine the effects of these inhibitors on
MET-amplified gastric cancer (GC) cells. Methods: After screening 37 GC cell lines, the following cell lines were found to be
MET-positive with copy number variation >10: SNU-620, ESO51, MKN-45, SNU-5, and OE33 cell lines. Next, we assessed the cytotoxic response of these cell lines to capmatinib or savolitinib alone using cell counting kit-8 and clonogenic cell survival assays. Western blotting was performed to assess the effects of capmatinib and savolitinib on the
MET signaling pathway. Xenograft studies were performed to evaluate the in vivo therapeutic efficacy of savolitinib in MKN-45 cells. Savolitinib and capmatinib exerted anti-proliferative effects on MET-amplified GC cell lines in a dose-dependent manner. Savolitinib inhibited the phosphorylation of
MET and downstream signaling pathways, such as the protein kinase B (AKT) and extracellular signal-regulated kinase (ERK) pathways, in
MET-amplified GC cells. Additionally, savolitinib significantly decreased the number of colonies formed on the soft agar and exerted dose-dependent anti-tumor effects in an MKN-45 GC cell xenograft model. Furthermore, a combination of trastuzumab and capmatinib exhibited enhanced inhibition of AKT and ERK activation in human epidermal growth factor receptor-2 (
HER2)- and
MET-positive OE33 cells. Targeting MET with savolitinib and capmatinib efficiently suppressed the growth of
MET-amplified GC cells. Moreover, these MET inhibitors exerted synergistic effects with trastuzumab on
HER2- and
MET-amplified GC cells.
Full article